SHAREHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2020


ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	Three months ended September 30				Nine months ended September 30
(In millions)	2020		2019		2020		2019
Beginning balance	$	47	$	59	$	61	$	(39)
AOCI before reclasses – net of taxes of $0, $15, $7 and $30(a)	3		30		44		151
Reclasses from AOCI – net of taxes of $2, $(3), $(12) and $(9)	5		(12)		(50)		(35)
AOCI	9		18		(5)		116
Less AOCI attributable to noncontrolling interests	—		—		—		—
Investment securities AOCI ending balance	$	55	$	77	$	55	$	77

Beginning balance	$	(4,743)	$	(5,874)	$	(4,818)	$	(6,134)
AOCI before reclasses – net of taxes of $(59), $(12), $(39) and $27	55		(189)		(558)		(191)
Reclasses from AOCI – net of taxes of $0, $(5), $0 and $(9)(b)	—		951		691		1,234
AOCI	55		762		133		1,043
Less AOCI attributable to noncontrolling interests	—		(63)		3		(41)
Currency translation adjustments AOCI ending balance	$	(4,689)	$	(5,050)	$	(4,689)	$	(5,050)

Beginning balance	$	(109)	$	26	$	49	$	13
AOCI before reclasses – net of taxes of $62, $(4), $(7) and $(1)	62		(30)		(160)		(43)
Reclasses from AOCI – net of taxes of $(13), $6, $(5) and $7(b)	(38)		28		26		56
AOCI	24		(2)		(134)		13
Less AOCI attributable to noncontrolling interests	—		1		—		2
Cash flow hedges AOCI ending balance	$	(86)	$	24	$	(86)	$	24

Beginning balance	$	(5,387)	$	(7,063)	$	(7,024)	$	(8,254)
AOCI before reclasses – net of taxes of $(22), $1, $6 and $36	(87)		39		58		(72)
Reclasses from AOCI – net of taxes of $187, $170, $613 and $517(b)	695		616		2,190		1,910
AOCI	609		655		2,248		1,838
Less AOCI attributable to noncontrolling interests	—		4		3		(4)
Benefit plans AOCI ending balance	$	(4,779)	$	(6,412)	$	(4,779)	$	(6,412)

AOCI at September 30	$	(9,498)	$	(11,361)	$	(9,498)	$	(11,361)

(a) Included adjustments of $(420) million and $(877) million for the three months ended September 30, 2020 and 2019, respectively and $(1,382) million and $(2,888) million for the nine months ended September 30, 2020 and 2019, respectively, related to insurance liabilities and annuity benefits in our run-off insurance operations to reflect the effects that would have been recognized had the related unrealized investment security gains been realized. See Note 12 for further information.

(b) The total reclassification from AOCI included $836 million, including currency translation of $688 million, net of taxes, for the nine months ended September 30, 2020, related to the sale of our BioPharma business within our Healthcare segment.